Istradefylline

Istradefylline
Clinical data
Trade names	Nourianz
Other names	KW-6002
AHFS/Drugs.com	Monograph
License data	US DailyMed: Istradefylline;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: ℞-only ;
Pharmacokinetic data
Protein binding	98%
Metabolism	Mainly CYP1A1, CYP3A4, and CYP3A5
Elimination half-life	64–69 hrs
Excretion	68% faeces, 18% urine
Identifiers
	IUPAC name 8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione;
CAS Number	155270-99-8 ;
PubChem CID	5311037;
IUPHAR/BPS	5608;
DrugBank	DB11757 ;
ChemSpider	4470574 ;
UNII	2GZ0LIK7T4;
KEGG	D04641 ;
ChEMBL	ChEMBL431770 ;
CompTox Dashboard (EPA)	DTXSID7057652 ;
ECHA InfoCard	100.230.117
Chemical and physical data
Formula	C20H24N4O4
Molar mass	384.436 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(c1nc(n(c1C(=O)N2CC)C)\C=C\c3ccc(OC)c(OC)c3)CC;
	InChI InChI=1S/C20H24N4O4/c1-6-23-18-17(19(25)24(7-2)20(23)26)22(3)16(21-18)11-9-13-8-10-14(27-4)15(12-13)28-5/h8-12H,6-7H2,1-5H3/b11-9+ ; Key:IQVRBWUUXZMOPW-PKNBQFBNSA-N ;
	(verify)

Istradefylline, sold under the brand name Nourianz, is a medication used as an add-on treatment to levodopa/carbidopa in adults with Parkinson's disease (PD) experiencing "off" episodes.[1][2][3] Istradefylline reduces "off" periods resulting from long-term treatment with the antiparkinson drug levodopa.[1] An "off" episode is a time when a patient's medications are not working well, causing an increase in PD symptoms, such as tremor and difficulty walking.[1]

Relatively common side effects include involuntary muscle movements (dyskinesia), constipation, hallucinations, dizziness and, much like its parent molecule caffeine, nausea and sleeplessness.[1] It is a selective antagonist at the A_2A receptor.

History

It was first approved in Japan in 2013.[4]

The effectiveness of Nourianz in treating "off" episodes in patients with Parkinson's disease who are already being treated with levodopa/carbidopa was shown in four 12-week placebo-controlled clinical studies that included a total of 1,143 participants. In all four studies, people treated with Nourianz experienced a statistically significant decrease from baseline in daily "off" time compared to patients receiving a placebo.[1][2]

It was approved for medical use in the United States in 2019.[1][2] and approval was granted to Kyowa Kirin, Inc.[1]

gollark: Yes they can?

gollark: See?

gollark: No, seems fine.

gollark: I might have to check.

gollark: You probably broke the entire apiary engine.

References

"FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease". U.S. Food and Drug Administration (FDA) (Press release). 27 August 2019. Archived from the original on 4 September 2019. Retrieved 29 August 2019. This article incorporates text from this source, which is in the public domain.
"Drug Trials Snapshots: Nourianz". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 20 November 2019. Retrieved 19 November 2019. This article incorporates text from this source, which is in the public domain.
Cabreira V, Soares-da-Silva P, Massano J (April 2019). "Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review". Drugs. 79 (6): 593–608. doi:10.1007/s40265-019-01098-w. PMID 30905034.
Dungo R, Deeks ED (June 2013). "Istradefylline: first global approval". Drugs. 73 (8): 875–82. doi:10.1007/s40265-013-0066-7. ISSN 1179-1950. PMID 23700273.

External links

"Istradefylline". Drug Information Portal. U.S. National Library of Medicine.
"Drug Approval Package: Nourianz". U.S. Food and Drug Administration (FDA).

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[FDA2019-1] "FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease". U.S. Food and Drug Administration (FDA) (Press release). 27 August 2019. Archived from the original on 4 September 2019. Retrieved 29 August 2019. This article incorporates text from this source, which is in the public domain.

[FDA_Snapshot-2] "Drug Trials Snapshots: Nourianz". U.S. Food and Drug Administration (FDA). 23 September 2019. Archived from the original on 20 November 2019. Retrieved 19 November 2019. This article incorporates text from this source, which is in the public domain.

[3] Cabreira V, Soares-da-Silva P, Massano J (April 2019). "Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review". Drugs. 79 (6): 593–608. doi:10.1007/s40265-019-01098-w. PMID 30905034.

[4] Dungo R, Deeks ED (June 2013). "Istradefylline: first global approval". Drugs. 73 (8): 875–82. doi:10.1007/s40265-013-0066-7. ISSN 1179-1950. PMID 23700273.